Stocks · News reference
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out yesterday.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings came out
The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.
The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.
Bristol Myers Squibb's SOTYKTU (deucravacitinib), a first-in-class TYK2 inhibitor, has received FDA approval for psoriatic arthritis in March 2026, expanding its commercial potential beyond plaque psoriasis. The drug demonstrates sustained efficacy with PASI 75 response rates of 67%-73% through five years and over 5,000 patient-years of safety data. Market analysis forecasts SOTYKTU sales across seven major markets through 2034, with growth driven by oral convenience, selective mechanism of action, and potential expansion into additional immune-mediated inflammatory disease indications including lupus, Sjogren's syndrome, and Crohn's disease.